Statin myopathy: Over-rated and under-treated

You'll have to demand your doctor figure out your myopathy.
http://www.mdlinx.com/internal-medicine/medical-news-article/2016/06/13/statin/6704352/?

Current Opinion in Cardiology, 06/13/2016Maghsoodi N, et al.

The purpose of this study is to conclude the definition of statin–related muscle disorders, causative factors, and recommended management strategies. Statin–related muscle adverse–effects are common. Secondary causes of muscle disease unmasked by statin therapy should be identified. Most patients can be managed by adjustment of standard treatment protocols.

• A number of consensus groups have defined and classified statin–related muscle disorders, whereas others have suggested diagnostic and management strategies. Mechanisms behind statin–related muscle toxicity have been identified.
• Therapeutic and clinical investigation pathways have been reviewed and algorithms defined.
• Novel drugs have become available to reduce low–density lipoprotein cholesterol levels that are not associated with causing muscle side–effects.

Go to PubMed Go to Abstract Print Article Summary Cat 2 CME Report

Molecular mechanisms of statin intolerance

Your doctor should be able to give you the exact percentage risks of developing these side effects. How many of their patients have discontinued statins because of side effects?
http://www.termedia.pl/Molecular-mechanisms-of-statin-intolerance,19,27579,0,1.html

Anna Gluba-Brzozka, Beata Franczyk, Peter P. Toth, Jacek Rysz, Maciej Banach

Arch Med Sci 2016; 12, 3: 645–658

DOI (digital object identifier): 10.5114/aoms.2016.59938

View full text

 

Statins reduce cardiovascular morbidity and mortality in primary and secondary prevention. Despite their efficacy, many persons are unable to tolerate statins due to adverse events such as hepatotoxicity and myalgia/myopathy. In the case of most patients, it seems that mild-to-moderate abnormalities in liver and muscle enzymes are not serious adverse effects and do not outweigh the benefits of coronary heart disease risk reduction. The risk for mortality or permanent organ damage ascribed to statin use is very small and limited to cases of myopathy and rhabdomyolysis. Statin-induced muscle-related adverse events comprise a highly heterogeneous clinical disorder with numerous, complex etiologies and a variety of genetic backgrounds. Every patient who presents with statin-related side effects cannot undergo the type of exhaustive molecular characterization that would include all of these mechanisms. Frequently the only solution is to either discontinue statin therapy/reduce the dose or attempt intermittent dosing strategies at a low dose.

Muscle problems caused by statins: Can a genetic test reveal your risk?

I do know a survivor who quit statins because of the myopathy it caused.

Muscle problems caused by statins: Can a genetic test reveal your risk?